Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, Ochoa CJ, Singh T, DiBernardo G, Guo W, Li S, Zhou Y, Yu[...]

Dopamine signaling drives skin invasion by human-infective nematodes

Patel R, Bartolo G, Castelletto ML, Garcia Romero A, Bryant AS, Agak GW, Hallem EA. Dopamine signaling drives skin invasion by human-infective nematodes. Nat Commun.[...]

Delayed diagnosis of pemphigus herpetiformis in a patient with dupilumab-associated hypereosinophilia

Smith SE, Swanson LA, Wonnaparhown A, DiCaudo DJ, Nelson SA, Kasperkiewicz M. Delayed diagnosis of pemphigus herpetiformis in a patient with dupilumab-associated hypereosinophilia. JAAD Case[...]